Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2025-11-18 00:00:00 ET · period of report 2025-11-17 · accession 0001628280-25-052841 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | 2025-11-17 | VIR | O'Byrne Jason | EVP, CFO | S - Sale | $5.56 | -6,799 | 110.7K | -6% | -$37.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-17 | S | D | 6,799 | $5.56 | 110,701 | D | — | — | (F2) Includes 2,500 shares of common stock acquired by the Reporting Person on May 30, 2025 pursuant to an employee stock purchase program. |